Healthcare
MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer’s Disease and Dementia
Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo.The LiBBY study evaluated MediPharm Labs’ proprietary oral cannabinoid formulation, developed and supplied exclusively by MediPharm Labs for use in the trial. TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or th
About this update from Medipharm Labs Corp.
TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specializing in precision-based cannabinoids, today announced positive results from the Phase II LiBBY (Life's End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company's proprietary oral cannabinoid formulation for the treatment of agitation in patients with advanced dementia. The results were presented by the LiBBY team at AAIC in London, United Kingdom on July 14, 2026. Addressing End-of-Life Agitation in Dementia The Alzheimer's Clinical Trial Consortium has shared that approximately 50% of people diagnosed with Alzheimer's disease or other types of dementia will receive hospice care at the end of their life1. Of these, more than 70% will be prescribed psychiatric medications for management of agitation2. In the absence of appropriate evidence-based guidelines, patients are typically prescribed a combination of antipsychotics, sedatives, and opiates. These medications often lead to undesirable side effects, lower the quality of life for patients, and cause additional burden to their care partners. The LiBBY randomized, double-blind, placebo-controlled study met its primary endpoint and demonstrated statistically significant improvements in agitation symptoms compared with placebo, with benefits observed as early as two weeks and sustained throughout the 12-week treatment period. Supportive findings from the open-label extension phase further demonstrated durability of response over time.3 The study evaluated MediPharm Labs' proprietary oral cannabinoid formulation, which was developed and supplied exclusively by MediPharm Labs for use in the trial. Greg Hunter, Interim CEO and CFO of MediPharm Labs, commented: "The positive LiBBY study results shared today represent an important milestone for patients living with advanced dementia, their families, and the advancement of cannabinoid-based medicines. The study findings are encouraging and add important clinical evidence in an area of urgent unmet need.
View stock analysis, news, and events for Medipharm Labs Corp.